Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERCEPT study of tocilizumab for late/chronic active antibody-mediated rejection after kidney transplantation
2024-510615-29-00Phase 3Authorised
- Sponsor
- Region Västra Götaland
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tocilizumab in humoral rejection and kidney allograft rejection (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Mean rate of change in eGFR decline. Planned start Mar 2024; status: authorised.
02
Drugs
tocilizumab
03
Conditions
humoral rejectionkidney allograft rejection
Beyond the preview
Go deeper on 2024-510615-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510615-29-00.